Emerging Advances in Nanocarriers Approaches in the Effective Therapy of Pain Related Disorders: Recent Evidence and Futuristic Needs
Sign Up to like & getrecommendations! Published in 2023 at "AAPS PharmSciTech"
DOI: 10.1208/s12249-023-02567-y
Abstract: Pain disorders are the primary cause of disability nowadays. These disorders, such as rheumatoid arthritis (RA) and osteoarthritis (OA), cause loss of function, joint pain and inflammation and deteriorate the quality of life. The treatment… read more here.
Keywords: pain disorders; emerging advances; advances nanocarriers; conventional therapies ... See more keywords
Non-conventional therapies for Peyronie's disease: what is the evidence for efficacy?
Sign Up to like & getrecommendations! Published in 2020 at "Translational andrology and urology"
DOI: 10.21037/tau.2019.09.36
Abstract: Background In recent years, there has been a surge in non-conventional therapies for Peyronie's disease (PD). With increasing interest in these novel therapies, we conducted a narrative review to explore the efficacy and safety of… read more here.
Keywords: peyronie disease; efficacy; non conventional; conventional therapies ... See more keywords
Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms
Sign Up to like & getrecommendations! Published in 2018 at "Cancers"
DOI: 10.3390/cancers10040124
Abstract: A growing body of evidence suggests that a subset of cells within tumors are resistant to conventional treatment modalities and may be responsible for disease recurrence. These cells are called cancer stem cells (CSC), which… read more here.
Keywords: conventional therapies; cancer stem; oncolytic viruses; cancer ... See more keywords
Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14030752
Abstract: Simple Summary Tyrosine kinase inhibitors (TKIs), including sorafenib and lenvatinib, have been the current standard treatment for advanced hepatocellular carcinoma (HCC) in cases where an immune checkpoint inhibitor cannot be used. The SHARP study showed… read more here.
Keywords: extrahepatic metastases; hepatocellular carcinoma; prognosis; patients extrahepatic ... See more keywords